My Blog List

Tuesday, 12 December 2017

Multiple Sclerosis (MS) Drugs Market share will expand till 2022

Description:

In this report, the EMEA Multiple Sclerosis (MS) Drugs market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.
Geographically, this report split EMEA into Europe, the Middle East and Africa, With sales (K Pcs), revenue (Million USD), market share and growth rate of Multiple Sclerosis (MS) Drugs for these regions, from 2012 to 2022 (forecast)
Europe: Germany, France, UK, Russia, Italy and Benelux;
Middle East: Saudi Arabia, Israel, UAE and Iran;
Africa: South Africa, Nigeria, Egypt and Algeria.


EMEA Multiple Sclerosis (MS) Drugs market competition by top manufacturers/players, with Multiple Sclerosis (MS) Drugs sales volume (K Pcs), price (USD/Pcs), revenue (Million USD) and market share for each manufacturer/player; the top players including
Bayer AG
Bayhill Therapeutics
Biogen Idec
Cinnagen
Daiichi Sankyo
Eli Lilly
Fast Forward Llc
Antisense Therapeutics
Apitope
Five Prime Therapeutics
Genmab
Artielle Immunotherapeutics
Genzyme
Glaxosmithkline
Gw Pharmaceuticals
Innate Immunotherapeutics


On the basis of product, this report displays the sales volume, revenue, product price, market share and growth rate of each type, primarily split into
Copaxone (Glatiramer Acetate, Copolymer 1)
Novantrone (Mitoxantrone)
Gilenya (Fingolimod, Fty720)
Aubagio (Teriflunomide)
Tecfidera (Dimethyl Fumarate)
Firategrast (Sb683699, T-0047)
Siponimod (Baf312)
Others
On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including
RRMS
SPMS
PPMS
PRMS

Make an Enquiry Of report for Discount @ https://www.reporthive.com/enquiry.php?id=1200043&req_type=disc

Table of Content:

1 Multiple Sclerosis (MS) Drugs Overview1.1 Product Overview and Scope of Multiple Sclerosis (MS) Drugs
1.2 Classification of Multiple Sclerosis (MS) Drugs
1.2.1 EMEA Multiple Sclerosis (MS) Drugs Market Size (Sales) Comparison by Type (2012–2022)
1.2.2 EMEA Multiple Sclerosis (MS) Drugs Market Size (Sales) Market Share by Type (Product Category) in 2016
1.2.3 Copaxone (Glatiramer Acetate, Copolymer 1)
1.2.4 Novantrone (Mitoxantrone)
1.2.5 Gilenya (Fingolimod, Fty720)
1.2.6 Aubagio (Teriflunomide)
1.2.7 Tecfidera (Dimethyl Fumarate)
1.2.8 Firategrast (Sb683699, T-0047)
1.2.9 Siponimod (Baf312)
1.2.10 Others
1.3 EMEA Multiple Sclerosis (MS) Drugs Market by Application/End Users
1.3.1 EMEA Multiple Sclerosis (MS) Drugs Sales (Volume) and Market Share Comparison by Application (2012–2022
1.3.2 RRMS
1.3.3 SPMS
1.3.4 PPMS
1.3.5 PRMS
1.4 EMEA Multiple Sclerosis (MS) Drugs Market by Region
1.4.1 EMEA Multiple Sclerosis (MS) Drugs Market Size (Value) Comparison by Region (2012–2022)
1.4.2 Europe Status and Prospect (2012–2022)
1.4.3 Middle East Status and Prospect (2012–2022)
1.4.4 Africa Status and Prospect (2012–2022)
1.5 EMEA Market Size (Value and Volume) of Multiple Sclerosis (MS) Drugs (2012–2022)
1.5.1 EMEA Multiple Sclerosis (MS) Drugs Sales and Growth Rate (2012–2022)
1.5.2 EMEA Multiple Sclerosis (MS) Drugs Revenue and Growth Rate (2012–2022)

2 EMEA Multiple Sclerosis (MS) Drugs Competition by Manufacturers/Players/Suppliers, Region, Type and Application2.1 EMEA Multiple Sclerosis (MS) Drugs Market Competition by Players/Manufacturers
2.1.1 EMEA Multiple Sclerosis (MS) Drugs Sales Volume and Market Share of Major Players (2012–2017)
2.1.2 EMEA Multiple Sclerosis (MS) Drugs Revenue and Share by Players (2012–2017)
2.1.3 EMEA Multiple Sclerosis (MS) Drugs Sale Price by Players (2012–2017)
2.2 EMEA Multiple Sclerosis (MS) Drugs (Volume and Value) by Type/Product Category
2.2.1 EMEA Multiple Sclerosis (MS) Drugs Sales and Market Share by Type (2012–2017)
2.2.2 EMEA Multiple Sclerosis (MS) Drugs Revenue and Market Share by Type (2012–2017)
2.2.3 EMEA Multiple Sclerosis (MS) Drugs Sale Price by Type (2012–2017)
2.3 EMEA Multiple Sclerosis (MS) Drugs (Volume) by Application
2.4 EMEA Multiple Sclerosis (MS) Drugs (Volume and Value) by Region
2.4.1 EMEA Multiple Sclerosis (MS) Drugs Sales and Market Share by Region (2012–2017)
2.4.2 EMEA Multiple Sclerosis (MS) Drugs Revenue and Market Share by Region (2012–2017)
2.4.3 EMEA Multiple Sclerosis (MS) Drugs Sales Price by Region (2012–2017)

About Report Hive Research

We are a leading repository of market research reports and solutions catering to industries like Comm & Technology, Energy & Power, Food And Beverages, Automotive & Transportation, Healthcare & Life Science etc. This large collection of reports assists organizations in decision-making on aspects such as market entry strategies, market sizing, market share analysis, competitive analysis, product portfolio analysis and opportunity analysis among others. We also assist in determining the best suited and targeted report from our large repository of global reports, company-specific reports and country-level reports.

Contact Us

Mike Ross
Marketing Manager
mike.ross@reporthive.com
http://www.reporthive.com
Phone: +1 312–604–7084
Sainath Nagar, Vadgaon Sheri,
Pune, Maharashtra 411014,
India